{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:02:55Z","timestamp":1778090575556,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.autrev.2021.102898","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:43:20Z","timestamp":1626353000000},"page":"102898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis"],"prefix":"10.1016","volume":"20","author":[{"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Due\u00f1a-Bartolome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Dunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimena","family":"Varona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlota","family":"Gomez-Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jokin","family":"Dominguez-Cainzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Rodrigo-Manjon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Duffau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estibaliz","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102898_bb0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2021.102898_bb0010","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102898_bb0015","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/0961203316671813","article-title":"Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage","volume":"26","author":"Joo","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2021.102898_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102898_bb0025","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102898_bb0030","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2021.102898_bb0035","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3899\/jrheum.120537","article-title":"Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study","volume":"39","author":"Fischer-Betz","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102898_bb0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","article-title":"Prednisone in lupus nephritis: how much is enough?","volume":"13","author":"Ruiz-Irastorza","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102898_bb0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2021.102898_bb0050","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102898_bb0055","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102898_bb0060","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2021.102898_bb0065","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102898_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2021.102898_bb0075","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102898_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102898_bb0085","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102898_bb0090","article-title":"Medium versus high initial prednisone dose for remission induction in lupus nephritis: a propensity score matched analysis","author":"Tselios","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102898_bb0095","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2021.102898_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2021.102898_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001299","article-title":"Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL)","volume":"6","author":"Re\u00e1tegui-Sokolova","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2021.102898_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2021.622225","article-title":"The use of glucocorticoids in lupus nephritis: new pathways for an old drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2021.102898_bb0115","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0961203320930099","article-title":"Seventy years after Hench\u2019s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Ruiz-Irastorza","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2021.102898_bb0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2015.05.011","article-title":"Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis","volume":"14","author":"Ruiz-Arruza","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102898_bb0125","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.autrev.2019.102359","article-title":"Prolonged remission in SLE is possible by using reduced doses of prednisone: an observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts","volume":"18","author":"Ruiz-Irastorza","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102898_bb0130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.23322","article-title":"Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study","volume":"70","author":"Ruiz-Arruza","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102898_bb0135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0961203319890007","article-title":"Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine","volume":"29","author":"Lee","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2021.102898_bb0140","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/ndt\/gfx318","article-title":"Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","volume":"33","author":"Cunha","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2021.102898_bb0145","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:23:48Z","timestamp":1761600228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1568997221001713"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102898","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102898"}}